Bayer Links

© Bayer MaterialScience AG

Drug-eluting coatings


BaymedixTM CD products are drug-eluting coatings that enable programmable release of a wide variety of actives, from small molecules to protein therapeutics. Biocompatibility of these systems has been demonstrated by in vitroand in vivo tests. More information is available in our product overview.


BaymedixTM CD 500 is a coatings platform for tailored drug release made using a unique blend of hydrophobic and hydrophilic polymers. Tunable release has been demonstrated with a variety of drugs, including sirolimus, paclitaxel, IL-1RA, dimethyloxalylglycine and dexamethasone.

Key Features of Baymedix CD 500 - Drug Eluting Coatings
  • Widely programmable release kinetics
  • Accommodates diverse targets: small molecules to protein therapeutics
  • Allows multiple, simultaneous drug release
  • Strong and flexible
  • Covalent bonding to metal: excellent adhesion
  • Withstands high deformations without cracking or flaking
  • Ethylene oxide and gamma irradiation sterilization compatible
  • Supported by in vivo(28 and 90 days) and in vitro safety data

Application Steps

1. Chemical functionalization of substrate
2. Polymer grafting to substrate – primer layer
3. Application of drug-eluting polymer blend
4. (Optional) Application of top-coat

Characteristics
  • Covalent attachment of coating to substrate for strong adhesion
  • High resistance to delamination in situ
  • Optional top-coat to modify release profile
  • Succesfully implemented on:stainless steel, cobalt-chromium, nitinol

For more information please click here (please login, e.g. register to download the document) or contact us.

Also, view this article on Qmed: "Drug-Delivery Technologies Show Some Backbone"

Login for registered Users